CRISPR Therapeutics AG
CRSP
$53.52
$1.883.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.39M | 4.10M | 3.51M | 38.34M | 38.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.39M | 4.10M | 3.51M | 38.34M | 38.05M |
| Cost of Revenue | 475.19M | 482.82M | 498.29M | 443.21M | 420.51M |
| Gross Profit | -461.80M | -478.71M | -494.78M | -404.88M | -382.46M |
| SG&A Expenses | 70.07M | 71.43M | 73.54M | 73.27M | 73.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 545.26M | 554.25M | 571.83M | 516.48M | 494.26M |
| Operating Income | -531.87M | -550.14M | -568.32M | -478.14M | -456.21M |
| Income Before Tax | -448.11M | -565.17M | -577.97M | -484.58M | -463.82M |
| Income Tax Expenses | 3.03M | 3.36M | 3.63M | 3.72M | 3.98M |
| Earnings from Continuing Operations | -451.14 | -568.53 | -581.60 | -488.30 | -467.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -451.14M | -568.53M | -581.60M | -488.30M | -467.80M |
| EBIT | -531.87M | -550.14M | -568.32M | -478.14M | -456.21M |
| EBITDA | -513.17M | -531.08M | -548.84M | -459.48M | -437.25M |
| EPS Basic | -4.76 | -6.21 | -6.51 | -5.58 | -5.42 |
| Normalized Basic EPS | -2.94 | -3.17 | -3.36 | -2.77 | -2.67 |
| EPS Diluted | -4.77 | -6.22 | -6.52 | -5.59 | -5.43 |
| Normalized Diluted EPS | -2.94 | -3.17 | -3.36 | -2.77 | -2.67 |
| Average Basic Shares Outstanding | 379.14M | 369.70M | 359.58M | 349.78M | 343.71M |
| Average Diluted Shares Outstanding | 379.14M | 369.70M | 359.58M | 349.78M | 343.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |